Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: The story does not give any estimate of the cost of Doppler ultrasound examinations. The story clearly states the reduction in fetal death rates the review authors calculated by combining the results of the studies ithey looked at. It reports the absolute risk calculation of fetal or newborn deaths (1.7 percent among women who did not receive ultrasound monitoring vs. 1.2 percent among those who did). This reporting of absolute (as opposed to relative) risk reduction is a strong point of the story since it conveys to readers that while the intervention did improve outcomes, the underlying risk is small. We only wish, however, that the story had cited the Number Needed to Test that was included in the study – 203 would need to be tested in order to find one case of fetal distress that would otherwise not have been seen using other routine exams. The story notes that there has been concern that the use of Doppler ultrasound might increase unnecessary interventions, including cesarean section deliveries in cases where it is not actually needed. It says the studies indicated that Doppler ultrasound appeared to lead to better decisions about cesarean sections and inductions of labor. The story explains that this report is a review of other studies. It also points out some shortcomings in the underlying studies. The story also includes a comment from one of the study authors that since the technique is established in current practice it is unlikely that there will be future studies of the use of the technology in high-risk pregnancies. The story clearly states that the evidence on the use of Doppler ultrasound applies only to high-risk pregnancies and that there is no evidence the examinations should be done in low-risk pregnancies. There is no information in the story that appears to come from an independent source. Comments from experts in the field would have helped put the authors’ comments into perspective. The story says other types of testing, including electronic fetal-heart monitoring, may also be done during high-risk pregnancies. The story notes that Doppler is an established technique used to monitor high-risk pregnancies. The story notes that Doppler ultrasound is an established technology and that most of the studies reviewed were done in the 1990s. The story does not appear to rely solely on a news release. It says the lead researcher was interviewed. Claim: Ultrasound may cut deaths in high-risk pregnancies

Ex Output:
This story clearly explains that a new review of the available evidence from published trials backs the use of Doppler ultrasound to monitor high-risk pregnancies. Notably, the story reports the absolute risk calculation of fetal or newborn deaths (1.7 percent among women who did not receive ultrasound monitoring vs. 1.2 percent among those who did), rather than trumpeting a large reduction in relative risk. By including the absolute risk numbers, the story helps readers understand both that the test appears to reduce the death rate and, importantly, that the overall risk of fetal or newborn death in developed nations is very small, thus putting the results in perspective. This story also pointed out that there is some uncertainty about the findings because of concerns about the quality of the underlying studies including in the review. What’s more, it highlights the point that the studies included only women who had high-risk pregnancies and that there is no evidence to suggest the use of Doppler ultrasound to monitor low-risk pregnancies. The story would have been ranked as satisfactory on all criteria if it had reported the typical cost of Doppler ultrasound monitoring and included an independent source in addition to the lead author of the review. When there is concern about potential problems with a pregnancy, Doppler ultrasound is a commonly recommended test used to help make decisions about cesarean section, induced labor or other interventions; thus misuse of the test could lead to inappropriate interventions.


Ex Input:
Paragraph: Limiting the quantity per dosage unit will reduce the risk of inadvertent overdose, which can lead to liver failure, liver transplant and death, the Food and Drug Administration said. It cited the fact that no available data showed that taking more than the recommended dose provided benefits that outweighed the added risks. (link.reuters.com/nen95v)  Inadvertent overdose from combination drugs containing acetaminophen, also known as paracetamol in most countries outside the United States, accounts for nearly half of all cases of acetaminophen-related liver failure in the United States, the agency said. Combination acetaminophen products are commonly prescribed to patients to treat pain from acute injuries, post-operative pain, or pain following dental procedures. In January 2011, the FDA asked manufacturers of combination drugs containing acetaminophen, sold globally under trade names such as Tylenol and Panadol, to limit acetaminophen doses to no more than 325 mg in each tablet or capsule by January 14, 2014. (link.reuters.com/hyn95v)  Some of these products still remain available, the agency said. The FDA also suggested that pharmacists who receive a prescription for a combination product with more than the recommended dose contact the prescriber to discuss using a lower dose. In the near future, the FDA plans to institute proceedings to withdraw approval for combination drugs that remain on the market, it said in a statement. Acetaminophen, one of the most commonly used drugs in the United States, is widely used in both prescription and over-the-counter products to reduce pain and fever. Claim: FDA asks doctors to limit acetaminophen in combination drugs.

Ex Output:
U.S. health regulators recommended on Tuesday that healthcare professionals stop prescribing combination drugs that contain more than 325 milligrams of acetaminophen per tablet, capsule, or other dosage unit, citing the risk of liver damage.


Ex Input:
Paragraph: Under the agreement, the “Yale Open Data Access Project,” will independently review and make final decisions regarding all requests for information on the company’s drug clinical trials, including anonymous patient data. The action comes amid growing pressure from outside scientists for access to raw data from clinical trials, reflecting general concerns that too many studies cannot be independently confirmed and may well be wrong. J&J, which sells drugs including blood thinner Xarelto and prostate cancer treatment Zytiga, said it is in the process of determining how best to share trial data from its other two areas of operation: medical devices and consumer products. “This is a multi-year effort on our part to try to contribute to advancing medical knowledge and science,” Joanne Waldstreicher, J&J’s chief medical officer, said in a telephone interview. Others drugmakers have made similar moves. Britain’s GlaxoSmithkline Plc has set up an online system to provide researchers with access to anonymous patient-level data about its medicines. Pfizer Inc said in December it would broaden access to information from its clinical trials to independent researchers and to patients who take part in the studies. Pfizer also set up an independent review panel of academic scientists to decide which researcher requests it would answer. Claim: J&J chooses Yale to review requests for clinical drug data.

Ex Output:

Johnson & Johnson has selected the Yale School of Medicine to review requests from investigators and physicians looking for access to clinical trial data involving the diversified healthcare company’s pharmaceuticals.